160 related articles for article (PubMed ID: 30226296)
1. Titration and optimization trial for the initiation of insulin glargine 100 U/mL in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs.
Seufert J; Fritsche A; Pscherer S; Anderten H; Borck A; Pegelow K; Bramlage P; Pfohl M
Diabetes Obes Metab; 2019 Feb; 21(2):439-443. PubMed ID: 30226296
[TBL] [Abstract][Full Text] [Related]
2. Titration of insulin glargine 100 U/mL when added to oral antidiabetic drugs in patients with type 2 diabetes: results of the TOP-1 real-world study.
Pscherer S; Anderten H; Pfohl M; Fritsche A; Borck A; Pegelow K; Bramlage P; Seufert J
Acta Diabetol; 2020 Jan; 57(1):89-99. PubMed ID: 31342163
[TBL] [Abstract][Full Text] [Related]
3. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2).
Terauchi Y; Koyama M; Cheng X; Takahashi Y; Riddle MC; Bolli GB; Hirose T
Diabetes Obes Metab; 2016 Apr; 18(4):366-74. PubMed ID: 26662838
[TBL] [Abstract][Full Text] [Related]
4. In Silico Examination of Initiation of Long-Acting Insulin Analogs Toujeo Compared to Lantus Under 3 Dosing Titration Rules in Virtual Type 2 Diabetes Subjects.
Sieber J; Weinheimer M; Kongable G; Riddle S; Chang YY; Flacke F
J Diabetes Sci Technol; 2020 Sep; 14(5):898-907. PubMed ID: 31288531
[TBL] [Abstract][Full Text] [Related]
5. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
Bolli GB; Riddle MC; Bergenstal RM; Ziemen M; Sestakauskas K; Goyeau H; Home PD;
Diabetes Obes Metab; 2015 Apr; 17(4):386-94. PubMed ID: 25641260
[TBL] [Abstract][Full Text] [Related]
6. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK.
Davies M; Evans R; Storms F; Gomis R; Khunti K
Diabetes Obes Metab; 2007 Sep; 9(5):706-13. PubMed ID: 17697063
[TBL] [Abstract][Full Text] [Related]
7. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension.
Riddle MC; Yki-Järvinen H; Bolli GB; Ziemen M; Muehlen-Bartmer I; Cissokho S; Home PD
Diabetes Obes Metab; 2015 Sep; 17(9):835-42. PubMed ID: 25846721
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and Safety of Physician-Led Versus Patient-Led Titration of Insulin Glargine in Indian Patients with Type 2 Diabetes Mellitus: A Subanalysis of the Asian Treat to Target Lantus Study (ATLAS).
Misra A; Patel M; Agarwal P; Lodha S; Tandon N; Magdum M; Yajnik C; Ghosh R; Walekar A
Diabetes Technol Ther; 2019 Nov; 21(11):656-664. PubMed ID: 31335198
[No Abstract] [Full Text] [Related]
9. Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulin-naive individuals with type 2 diabetes mellitus.
Frier BM; Landgraf W; Zhang M; Bolli GB; Owens DR
Diabetes Obes Metab; 2018 Dec; 20(12):2894-2898. PubMed ID: 29943493
[TBL] [Abstract][Full Text] [Related]
10. HbA1c target achievement in the elderly: results of the Titration and Optimization trial for initiation of insulin glargine 100 U/mL in patients with type 2 diabetes poorly controlled on oral antidiabetic drugs.
Fritsche A; Anderten H; Pfohl M; Pscherer S; Borck A; Pegelow K; Bramlage P; Seufert J
BMJ Open Diabetes Res Care; 2019; 7(1):e000668. PubMed ID: 31423316
[TBL] [Abstract][Full Text] [Related]
11. Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes.
Owens DR; Bolli GB; Charbonnel B; Haak T; Landgraf W; Porcellati F; Traylor L; Kautzky-Willer A
Diabetes Obes Metab; 2017 Nov; 19(11):1546-1554. PubMed ID: 28449412
[TBL] [Abstract][Full Text] [Related]
12. Similar glycaemic control and risk of hypoglycaemia with patient- versus physician-managed titration of insulin glargine 300 U/mL across subgroups of patients with T2DM: a post hoc analysis of ITAS.
Giaccari A; Bonadonna RC; Buzzetti R; Perseghin G; Cucinotta D; Fanelli C; Avogaro A; Aimaretti G; Larosa M; Pagano V; Bolli GB
Acta Diabetol; 2021 Jun; 58(6):789-796. PubMed ID: 33586058
[TBL] [Abstract][Full Text] [Related]
13. Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: A 12-month comparison by concomitant sulphonylurea and/or glinide use.
Terauchi Y; Riddle MC; Hirose T; Koyama M; Cheng X; Takahashi Y; Bolli GB
Diabetes Obes Metab; 2018 Nov; 20(11):2541-2550. PubMed ID: 29888454
[TBL] [Abstract][Full Text] [Related]
14. Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension).
Terauchi Y; Koyama M; Cheng X; Sumi M; Riddle MC; Bolli GB; Hirose T;
Diabetes Metab; 2017 Oct; 43(5):446-452. PubMed ID: 28433560
[TBL] [Abstract][Full Text] [Related]
15. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes.
Ritzel R; Roussel R; Bolli GB; Vinet L; Brulle-Wohlhueter C; Glezer S; Yki-Järvinen H
Diabetes Obes Metab; 2015 Sep; 17(9):859-67. PubMed ID: 25929311
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial.
Hollander PA; Carofano WL; Lam RLH; Golm GT; Eldor R; Crutchlow MF; Marcos MC; Rendell MS; Home PD; Gallwitz B; Rosenstock J
Diabetes Obes Metab; 2018 Sep; 20(9):2229-2237. PubMed ID: 29761615
[TBL] [Abstract][Full Text] [Related]
17. Dosing of insulin glargine in the treatment of type 2 diabetes.
Barnett A
Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of High Versus Standard Starting Doses of Insulin Glargine in Overweight and Obese Chinese Individuals with Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Medications (Beyond VII): Study Protocol for a Randomized Controlled Trial.
Ji L; Gao Z; Shi B; Bian R; Yin F; Pang W; Gao H; Cui N
Adv Ther; 2018 Jun; 35(6):864-874. PubMed ID: 29873004
[TBL] [Abstract][Full Text] [Related]
19. Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0.
Owens DR; Landgraf W; Frier BM; Zhang M; Home PD; Meneghini L; Bolli GB
Diabetes Obes Metab; 2019 Feb; 21(2):321-329. PubMed ID: 30520217
[TBL] [Abstract][Full Text] [Related]
20. Real-World Data Collection Regarding Titration Algorithms for Insulin Glargine in Patients With Type 2 Diabetes Mellitus.
Pfützner A; Stratmann B; Funke K; Pohlmeier H; Rose L; Sieber J; Flacke F; Tschoepe D
J Diabetes Sci Technol; 2016 Sep; 10(5):1122-9. PubMed ID: 27325389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
